References

  1. Schaller T, Herold N. The Early Bird Catches the Worm - Can Evolution Teach us Lessons in Fighting HIV? Current HIV Research. 2016;14(3):183-210. PubMed | Google Scholar

  2. Suleiman IA, Momo A. Adherence to antiretroviral therapy and its determinants among persons living with HIV/AIDS in Bayelsa state, Nigeria. Pharmacy Practice. 2016;14(1): 631. PubMed | Google Scholar

  3. Teshome W, Tefera A. Detection of immunological treatment failure among HIV infected patients in Ethiopia? a retrospective cohort study. BMC Immunology. 2015 Sep 16;16:55. PubMed | Google Scholar

  4. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization’s global antiretroviral guidance. Journal of the International AIDS Society. 2013 Jun 30;16:18757. PubMed | Google Scholar

  5. National Institute of Statistics of Rwanda. DHS report retrieved from http://www.measuredhs.com/pubs/pdf/PR7/PR7.pdf. 2010. Google Scholar

  6. Twizerimana AP, Mwatha J, Musabyimana JP, Kayigi E, Harelimana JD, Karanja SM, Mutesa L. Immunological profiles in HIV positive patients following HAART initiation in Kigali, Rwanda. East African Medical Journal. 2014;91(8):261-6. PubMed | Google Scholar

  7. Nanzigu S, Kiguba R, Kabanda J, Mukonzo JK, Waako P, Kityo C, Makumbi F. Poor immunological recovery among severely immunosuppressed antiretroviral therapy-nave Ugandans. HIV/AIDS - Research and Palliative Care. 2013;5:309-319. PubMed | Google Scholar

  8. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006 May 12;20(8):1141-50. PubMed | Google Scholar

  9. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23;24(16):2469-79. PubMed | Google Scholar

  10. Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB et al. Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One. 2013 Sep 30;8(9):e76071. PubMed | Google Scholar

  11. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J et al. Long-term mortality in HIVpositive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014 May;58(9):1312-21. PubMed | Google Scholar

  12. Lodi S et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV. 2015;2(8): 335-43. PubMed | Google Scholar

  13. WHO. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance available at http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf. 2005. Retrieved on 26.07.2016. PubMed | Google Scholar

  14. Ingole NA, Kukreja SM, Mehta PR. Role of HIV-1 viral load in initiating antiretroviral therapy. World Journal of AIDS. 2011; 01(04):149-154. PubMed | Google Scholar

  15. Lahuerta MU, Hoffman S, Elul B, Kulkarni SG, Wu Y, Nash D. The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?. Journal of Health Care for the Poor and Underserved. 2013;24(1):359-83. PubMed | Google Scholar

  16. Moore RD, Keruly JC. CD4+ cell count 6 years aftercommencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clinical infectious diseases. 2007;44(3):441-446. PubMed | Google Scholar

  17. Olubajo B, Mitchell F K, Ogunmoroti O. A comparative systematic review of the optimal CD4 cell count threshold for HIV treatment initiation. Interdisciplinary Perspectives on Infectious Diseases. 2014; 7–12. Google Scholar

  18. Boniphace I, Omari M, Susan Fred R, Ferdinand M, Marcel T. HIV/AIDS clinical manifestations and their Implication for patient clinical staging in resource limited settings in Tanzania. The Open AIDS Journal. 2011;5:9-16. PubMed | Google Scholar

  19. Gatell JM. When and why to start antiretroviral therapy? The Journal of Antimicrobial Chemotherapy. 2010;65(3):38-5. PubMed | Google Scholar

  20. Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Abraham OC. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Indian Journal of Medical Microbiology. 2009;27(3):231-6. PubMed | Google Scholar

  21. Prabhakar B, Banu A, Pavithra HB, Chandrashekhara P, Sasthri S. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian Journal of Sexually Transmitted Diseases. 2011;32(2):94-8. PubMed | Google Scholar

  22. Geng EH, Deeks SG. CD4+ T cell recovery with antiretroviral therapy: more than the sum of the parts. Clinical Infectious Diseases? An Official Publication of the Infectious Diseases Society of America. 2009;48(3):362-4. PubMed | Google Scholar

  23. Nasi M, Pinti M, Bugarini R, Troiano L, Lugli E, Bellodi C, Cossarizza A. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients. Immunogenetics. 2005;57(9):628-35. PubMed | Google Scholar

  24. Annison L, Dompreh A. The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital. Ghana medical journal. 2013;47(4):164-70. PubMed | Google Scholar